{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:33:36Z","timestamp":1794918816303,"version":"4.9.1"},"reference-count":25,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8240050579"],"award-info":[{"award-number":["8240050579"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NeuroDawn Pharmaceutical Co., Ltd","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Loberamisal is a small-molecule agent that inhibits the nNOS-postsynaptic density protein 95 coupling and enhances \u03b12-containing \u03b3-aminobutyric acid type A receptor, which has been shown effective in animal studies. This trial aimed to investigate its safety and therapeutic efficacy in patients with acute ischaemic stroke (AIS) within 48 hours of symptom onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomly assigned in a 1:1:1:1 ratio to one of four groups: a low-dose loberamisal group (20\u2009mg\/dose), a medium-dose group (40\u2009mg\/dose), a high-dose group (60\u2009mg\/dose) or a placebo group. All patients received a continuous intravenous infusion treatment once a day for 10 days (60\u00b110\u2009min\/dose). The primary efficacy outcome was the proportion of patients achieving an excellent functional outcome (a modified Rankin Scale score of 0\u20131 at 90 days). The primary safety outcome was the incidence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 240 patients were randomised, of whom 224 received study treatment from 4 June 2023 to 18 November 2023. The proportion of patients with excellent functional outcome was highest in the medium-dose group (76.7%, 46\/60), followed by the high-dose group (70.0%, 42\/60), the low-dose group (67.8%, 40\/59) and the placebo group (60.7%, 37\/61) (p=0.164). Regarding safety, 210 patients experienced at least one AE, with incidences of 80.0% (48\/60), 88.3% (53\/60) and 91.5% (54\/59) in the high, medium and low-dose loberamisal groups, respectively, and 90.2% (55\/61) in the placebo group (p=0.260).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Loberamisal injection was well tolerated in patients with AIS within 48 hours of symptom onset in China. The efficacy and optimal dosage of loberamisal for AIS need prospective validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ChiCTR2400081662,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06429384\">NCT06429384<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2025-004581","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:55:20Z","timestamp":1762847720000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Loberamisal injection for the treatment of acute ischaemic stroke: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct06429384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06429384","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Baoyu","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Clinical Trial Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-4105","authenticated-orcid":false,"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-5147","authenticated-orcid":false,"given":"Xingquan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[{"name":"Harrison International Peace Hospital, Hengshui, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Nanyang Nanshi Hospital, Nanyang, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Wang","sequence":"additional","affiliation":[{"name":"Baogang Hospital of Inner Mongolia, Baotou, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-2341","authenticated-orcid":false,"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"},{"name":"Department of Neurology, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-0365","authenticated-orcid":false,"given":"Shuya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"},{"name":"Department of Neurology, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2026082702101062000_11.4.465.1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.031869"},{"key":"2026082702101062000_11.4.465.2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211"},{"key":"2026082702101062000_11.4.465.3","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026082702101062000_11.4.465.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac684"},{"key":"2026082702101062000_11.4.465.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00605-6"},{"key":"2026082702101062000_11.4.465.6","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2026082702101062000_11.4.465.7","doi-asserted-by":"crossref","DOI":"10.1136\/svn-2023-002998","article-title":"Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update","volume":"8","author":"Liu","year":"2023","journal-title":"Stroke Vasc Neurol"},{"key":"2026082702101062000_11.4.465.8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2245"},{"key":"2026082702101062000_11.4.465.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30258-0"},{"key":"2026082702101062000_11.4.465.10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0140-6736(25)00194-1","article-title":"Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial","volume":"405","author":"Hill","year":"2025","journal-title":"Lancet"},{"key":"2026082702101062000_11.4.465.11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(25)00193-X","article-title":"Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study","volume":"405","author":"Christenson","year":"2025","journal-title":"Lancet"},{"key":"2026082702101062000_11.4.465.12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(24)00515-5","article-title":"Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials","volume":"24","author":"Tymianski","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026082702101062000_11.4.465.13","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-015-9661-9"},{"key":"2026082702101062000_11.4.465.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110142"},{"key":"2026082702101062000_11.4.465.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-015-9283-2"},{"key":"2026082702101062000_11.4.465.16","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.7150\/thno.58364","article-title":"A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and \u03b12-containning GABA A Rs","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"2026082702101062000_11.4.465.17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s13311-020-00883-w","article-title":"Prolonged Use of NMDAR Antagonist Develops Analgesic Tolerance in Neuropathic Pain via Nitric Oxide Reduction-Induced GABAergic Disinhibition","volume":"17","author":"Li","year":"2020","journal-title":"Neurotherapeutics"},{"key":"2026082702101062000_11.4.465.18","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2022-002156"},{"key":"2026082702101062000_11.4.465.19","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.034947"},{"key":"2026082702101062000_11.4.465.20","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s13311-021-01158-8","article-title":"A Compound Mitigates Cancer Pain and Chemotherapy-Induced Neuropathic Pain by Dually Targeting nNOS-PSD-95 Interaction and GABAA Receptor","volume":"18","author":"Wei","year":"2021","journal-title":"Neurotherapeutics"},{"key":"2026082702101062000_11.4.465.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3502"},{"key":"2026082702101062000_11.4.465.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.10.011"},{"key":"2026082702101062000_11.4.465.23","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30004-1"},{"key":"2026082702101062000_11.4.465.24","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70016-x"},{"key":"2026082702101062000_11.4.465.25","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.46"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2025-004581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:10:55Z","timestamp":1787821855000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2025-004581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,27]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/svn-2025-004581"],"URL":"https:\/\/doi.org\/10.1136\/svn-2025-004581","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}